LOS ANGELES -- Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. Results of their study, being presented today at the American Association for Cancer Research annual meeting, show the by-product to be more effective than currently used therapies at killing multiple myeloma cells. The complete findings are also available online in Blood.
"There were a number of fascinating findings," says Keith Bible, M.D., Ph.D., oncologist and the studys primary investigator. "In addition to observing many favorable aspects of chaetocin, we discovered some avenues for further research into other possible anti-myeloma agents."
Multiple myeloma is an incurable bone marrow cancer that kills more than 11,000 people each year in the United States, reports the American Cancer Society. Dr. Bibles team has shown for the first time that chaetocin has promising anti-myeloma activity. They found that chaetocins promise includes the ability to:
The researchers were surprised that chaetocin, while structurally similar to anti-cancer agents known as histone deacetylase inhibitors (HDACIs), did not, at cytotoxic concentrations, seem to function as an HDACI; but instead that the cytotoxic mechanism appeared to be at least in part attributable to oxidative stress caused by chaetocin.
"Much more research needs to be done," says Jennifer Tibodeau, Mayo post-doctorate fellow and presenter of the study, "but we are hopeful that chaetocin may some day provide ne
Contact: Elizabeth Zimmermann